Loading…

Thermoreversible mucoadhesive polymer-drug dispersion for sustained local delivery of budesonide to treat inflammatory disorders of the GI tract

Mucoadhesive drug formulations have been studied and used as alternatives to conventional formulations in order to achieve prolonged retention at the intended site. In addition to providing a controlled drug release, several drugs and disease conditions might benefit from mucoadhesive formulations,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2019-06, Vol.303, p.12-23
Main Authors: Antonino, Rayane S C M Q, Nascimento, Thais L, de Oliveira Junior, Edilson R, Souza, Leonardo G, Batista, Aline C, Lima, Eliana M
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c346t-a3aca2bdf44620df909c0d609af95be93b82c0f7525d08a0bb90bc3768d26eb93
cites cdi_FETCH-LOGICAL-c346t-a3aca2bdf44620df909c0d609af95be93b82c0f7525d08a0bb90bc3768d26eb93
container_end_page 23
container_issue
container_start_page 12
container_title Journal of controlled release
container_volume 303
creator Antonino, Rayane S C M Q
Nascimento, Thais L
de Oliveira Junior, Edilson R
Souza, Leonardo G
Batista, Aline C
Lima, Eliana M
description Mucoadhesive drug formulations have been studied and used as alternatives to conventional formulations in order to achieve prolonged retention at the intended site. In addition to providing a controlled drug release, several drugs and disease conditions might benefit from mucoadhesive formulations, contributing to better therapeutic outcomes. Here, we describe the development and the in vitro/in vivo characterization of a mucoadhesive in situ gellifying formulation using PF127, a thermo reversible polymer, entrapping budesonide (BUD), a potent corticosteroid used for the treatment of a wide range of inflammatory diseases, including those affecting mucosas, such as in the GI tract. PF127 formulations (15-17%) were successfully prepared by a cold method as a thermo reversible in situ gelling dispersion for mucosal drug delivery, as confirmed by DSC. Sol-gel temperatures of PF127 formulations (25-39 °C) were observed by dynamic gelation and determined by microrheology and oscillatory rheometry. X-ray diffractograms and TEM images showed that BUD was completely solubilized within the polymeric micelles. In vitro, the gels showed 5-14 g force of mucoadhesion, and the ex vivo studies confirmed that the formulation efficiently adhered to the mucosa. Histopathological analysis combined with fluorescence images and ex vivo intestinal permeation confirmed that the formulation remained on the TGI mucosa for at least 4 h after administration. In vivo studies conducted in a murine model of intestinal mucositis demonstrated that the 16% PF127 BUD formulation was able to resolve the inflammatory injury in the intestinal mucosa. Results demonstrate that fine-tuning of PF127 formulations along with adequate selection of the drug agent, thorough characterization of the dispersions and their interactions with biological interfaces leads to the development of effective controlled drug delivery systems targeted to GI inflammatory diseases.
doi_str_mv 10.1016/j.jconrel.2019.04.011
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2209605559</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2209605559</sourcerecordid><originalsourceid>FETCH-LOGICAL-c346t-a3aca2bdf44620df909c0d609af95be93b82c0f7525d08a0bb90bc3768d26eb93</originalsourceid><addsrcrecordid>eNo9kctu2zAQRYmiRe26_YQGXHYjZSSKsrgsgjQNYCAbd03wMaxlUKJDUgb8F_3kSLDT1WzOvReYQ8j3CsoKqvb-WB5NGCP6soZKlNCUUFUfyLrqtqxohOAfyXrmuoK1XKzIl5SOAMBZs_1MVgxEBx1na_Jvf8A4hIhnjKnXHukwmaDsAVN_RnoK_jJgLGyc_lLbp9NChZG6EGmaUlb9iJb6YJSnFv0ciRcaHNWTxRTG3iLNgeaIKtN-dF4Ng8phZuauEO3cttD5gPTpecaUyV_JJ6d8wm-3uyF_fj3uH34Xu5en54efu8Kwps2FYsqoWlvXNG0N1gkQBmwLQjnBNQqmu9qA2_KaW-gUaC1AG7ZtO1u3qAXbkB_X3lMMrxOmLIc-GfRejRimJOsaRAuc8wXlV9TEkFJEJ0-xH1S8yArkIkMe5U2GXGRIaOQsY87d3SYmPaD9n3r_PnsDvsSM0g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2209605559</pqid></control><display><type>article</type><title>Thermoreversible mucoadhesive polymer-drug dispersion for sustained local delivery of budesonide to treat inflammatory disorders of the GI tract</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Antonino, Rayane S C M Q ; Nascimento, Thais L ; de Oliveira Junior, Edilson R ; Souza, Leonardo G ; Batista, Aline C ; Lima, Eliana M</creator><creatorcontrib>Antonino, Rayane S C M Q ; Nascimento, Thais L ; de Oliveira Junior, Edilson R ; Souza, Leonardo G ; Batista, Aline C ; Lima, Eliana M</creatorcontrib><description>Mucoadhesive drug formulations have been studied and used as alternatives to conventional formulations in order to achieve prolonged retention at the intended site. In addition to providing a controlled drug release, several drugs and disease conditions might benefit from mucoadhesive formulations, contributing to better therapeutic outcomes. Here, we describe the development and the in vitro/in vivo characterization of a mucoadhesive in situ gellifying formulation using PF127, a thermo reversible polymer, entrapping budesonide (BUD), a potent corticosteroid used for the treatment of a wide range of inflammatory diseases, including those affecting mucosas, such as in the GI tract. PF127 formulations (15-17%) were successfully prepared by a cold method as a thermo reversible in situ gelling dispersion for mucosal drug delivery, as confirmed by DSC. Sol-gel temperatures of PF127 formulations (25-39 °C) were observed by dynamic gelation and determined by microrheology and oscillatory rheometry. X-ray diffractograms and TEM images showed that BUD was completely solubilized within the polymeric micelles. In vitro, the gels showed 5-14 g force of mucoadhesion, and the ex vivo studies confirmed that the formulation efficiently adhered to the mucosa. Histopathological analysis combined with fluorescence images and ex vivo intestinal permeation confirmed that the formulation remained on the TGI mucosa for at least 4 h after administration. In vivo studies conducted in a murine model of intestinal mucositis demonstrated that the 16% PF127 BUD formulation was able to resolve the inflammatory injury in the intestinal mucosa. Results demonstrate that fine-tuning of PF127 formulations along with adequate selection of the drug agent, thorough characterization of the dispersions and their interactions with biological interfaces leads to the development of effective controlled drug delivery systems targeted to GI inflammatory diseases.</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2019.04.011</identifier><identifier>PMID: 30980853</identifier><language>eng</language><publisher>Netherlands</publisher><ispartof>Journal of controlled release, 2019-06, Vol.303, p.12-23</ispartof><rights>Copyright © 2019 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c346t-a3aca2bdf44620df909c0d609af95be93b82c0f7525d08a0bb90bc3768d26eb93</citedby><cites>FETCH-LOGICAL-c346t-a3aca2bdf44620df909c0d609af95be93b82c0f7525d08a0bb90bc3768d26eb93</cites><orcidid>0000-0003-1231-5803</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30980853$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Antonino, Rayane S C M Q</creatorcontrib><creatorcontrib>Nascimento, Thais L</creatorcontrib><creatorcontrib>de Oliveira Junior, Edilson R</creatorcontrib><creatorcontrib>Souza, Leonardo G</creatorcontrib><creatorcontrib>Batista, Aline C</creatorcontrib><creatorcontrib>Lima, Eliana M</creatorcontrib><title>Thermoreversible mucoadhesive polymer-drug dispersion for sustained local delivery of budesonide to treat inflammatory disorders of the GI tract</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Mucoadhesive drug formulations have been studied and used as alternatives to conventional formulations in order to achieve prolonged retention at the intended site. In addition to providing a controlled drug release, several drugs and disease conditions might benefit from mucoadhesive formulations, contributing to better therapeutic outcomes. Here, we describe the development and the in vitro/in vivo characterization of a mucoadhesive in situ gellifying formulation using PF127, a thermo reversible polymer, entrapping budesonide (BUD), a potent corticosteroid used for the treatment of a wide range of inflammatory diseases, including those affecting mucosas, such as in the GI tract. PF127 formulations (15-17%) were successfully prepared by a cold method as a thermo reversible in situ gelling dispersion for mucosal drug delivery, as confirmed by DSC. Sol-gel temperatures of PF127 formulations (25-39 °C) were observed by dynamic gelation and determined by microrheology and oscillatory rheometry. X-ray diffractograms and TEM images showed that BUD was completely solubilized within the polymeric micelles. In vitro, the gels showed 5-14 g force of mucoadhesion, and the ex vivo studies confirmed that the formulation efficiently adhered to the mucosa. Histopathological analysis combined with fluorescence images and ex vivo intestinal permeation confirmed that the formulation remained on the TGI mucosa for at least 4 h after administration. In vivo studies conducted in a murine model of intestinal mucositis demonstrated that the 16% PF127 BUD formulation was able to resolve the inflammatory injury in the intestinal mucosa. Results demonstrate that fine-tuning of PF127 formulations along with adequate selection of the drug agent, thorough characterization of the dispersions and their interactions with biological interfaces leads to the development of effective controlled drug delivery systems targeted to GI inflammatory diseases.</description><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNo9kctu2zAQRYmiRe26_YQGXHYjZSSKsrgsgjQNYCAbd03wMaxlUKJDUgb8F_3kSLDT1WzOvReYQ8j3CsoKqvb-WB5NGCP6soZKlNCUUFUfyLrqtqxohOAfyXrmuoK1XKzIl5SOAMBZs_1MVgxEBx1na_Jvf8A4hIhnjKnXHukwmaDsAVN_RnoK_jJgLGyc_lLbp9NChZG6EGmaUlb9iJb6YJSnFv0ciRcaHNWTxRTG3iLNgeaIKtN-dF4Ng8phZuauEO3cttD5gPTpecaUyV_JJ6d8wm-3uyF_fj3uH34Xu5en54efu8Kwps2FYsqoWlvXNG0N1gkQBmwLQjnBNQqmu9qA2_KaW-gUaC1AG7ZtO1u3qAXbkB_X3lMMrxOmLIc-GfRejRimJOsaRAuc8wXlV9TEkFJEJ0-xH1S8yArkIkMe5U2GXGRIaOQsY87d3SYmPaD9n3r_PnsDvsSM0g</recordid><startdate>20190610</startdate><enddate>20190610</enddate><creator>Antonino, Rayane S C M Q</creator><creator>Nascimento, Thais L</creator><creator>de Oliveira Junior, Edilson R</creator><creator>Souza, Leonardo G</creator><creator>Batista, Aline C</creator><creator>Lima, Eliana M</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1231-5803</orcidid></search><sort><creationdate>20190610</creationdate><title>Thermoreversible mucoadhesive polymer-drug dispersion for sustained local delivery of budesonide to treat inflammatory disorders of the GI tract</title><author>Antonino, Rayane S C M Q ; Nascimento, Thais L ; de Oliveira Junior, Edilson R ; Souza, Leonardo G ; Batista, Aline C ; Lima, Eliana M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c346t-a3aca2bdf44620df909c0d609af95be93b82c0f7525d08a0bb90bc3768d26eb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Antonino, Rayane S C M Q</creatorcontrib><creatorcontrib>Nascimento, Thais L</creatorcontrib><creatorcontrib>de Oliveira Junior, Edilson R</creatorcontrib><creatorcontrib>Souza, Leonardo G</creatorcontrib><creatorcontrib>Batista, Aline C</creatorcontrib><creatorcontrib>Lima, Eliana M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Antonino, Rayane S C M Q</au><au>Nascimento, Thais L</au><au>de Oliveira Junior, Edilson R</au><au>Souza, Leonardo G</au><au>Batista, Aline C</au><au>Lima, Eliana M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thermoreversible mucoadhesive polymer-drug dispersion for sustained local delivery of budesonide to treat inflammatory disorders of the GI tract</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2019-06-10</date><risdate>2019</risdate><volume>303</volume><spage>12</spage><epage>23</epage><pages>12-23</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>Mucoadhesive drug formulations have been studied and used as alternatives to conventional formulations in order to achieve prolonged retention at the intended site. In addition to providing a controlled drug release, several drugs and disease conditions might benefit from mucoadhesive formulations, contributing to better therapeutic outcomes. Here, we describe the development and the in vitro/in vivo characterization of a mucoadhesive in situ gellifying formulation using PF127, a thermo reversible polymer, entrapping budesonide (BUD), a potent corticosteroid used for the treatment of a wide range of inflammatory diseases, including those affecting mucosas, such as in the GI tract. PF127 formulations (15-17%) were successfully prepared by a cold method as a thermo reversible in situ gelling dispersion for mucosal drug delivery, as confirmed by DSC. Sol-gel temperatures of PF127 formulations (25-39 °C) were observed by dynamic gelation and determined by microrheology and oscillatory rheometry. X-ray diffractograms and TEM images showed that BUD was completely solubilized within the polymeric micelles. In vitro, the gels showed 5-14 g force of mucoadhesion, and the ex vivo studies confirmed that the formulation efficiently adhered to the mucosa. Histopathological analysis combined with fluorescence images and ex vivo intestinal permeation confirmed that the formulation remained on the TGI mucosa for at least 4 h after administration. In vivo studies conducted in a murine model of intestinal mucositis demonstrated that the 16% PF127 BUD formulation was able to resolve the inflammatory injury in the intestinal mucosa. Results demonstrate that fine-tuning of PF127 formulations along with adequate selection of the drug agent, thorough characterization of the dispersions and their interactions with biological interfaces leads to the development of effective controlled drug delivery systems targeted to GI inflammatory diseases.</abstract><cop>Netherlands</cop><pmid>30980853</pmid><doi>10.1016/j.jconrel.2019.04.011</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-1231-5803</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0168-3659
ispartof Journal of controlled release, 2019-06, Vol.303, p.12-23
issn 0168-3659
1873-4995
language eng
recordid cdi_proquest_miscellaneous_2209605559
source Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)
title Thermoreversible mucoadhesive polymer-drug dispersion for sustained local delivery of budesonide to treat inflammatory disorders of the GI tract
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A16%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thermoreversible%20mucoadhesive%20polymer-drug%20dispersion%20for%20sustained%20local%20delivery%20of%20budesonide%20to%20treat%20inflammatory%20disorders%20of%20the%20GI%20tract&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Antonino,%20Rayane%20S%20C%20M%20Q&rft.date=2019-06-10&rft.volume=303&rft.spage=12&rft.epage=23&rft.pages=12-23&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2019.04.011&rft_dat=%3Cproquest_cross%3E2209605559%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c346t-a3aca2bdf44620df909c0d609af95be93b82c0f7525d08a0bb90bc3768d26eb93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2209605559&rft_id=info:pmid/30980853&rfr_iscdi=true